Mesa Laboratories, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2016. The request metadata identifies “2014 Q4,” but the supplied filing is the FY2016 annual report, filed June 6, 2016.
Business Context
Mesa develops and sells regulated quality-control products and services through four divisions: Biological Indicators, Instruments, Continuous Monitoring, and Cold Chain. Its markets include healthcare, pharmaceutical, medical device, food and beverage, environmental monitoring, and industrial applications. The company emphasizes niche markets, regulatory-driven demand, high gross margins, distribution expansion, new products, and acquisitions.
Mesa completed ten acquisitions during fiscal 2016, including Infitrak, North Bay, and multiple European biological-indicator distributors. It also completed the ATS and Pulse acquisitions in April 2016 after year-end.
Financial Performance and Liquidity
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $84.659 million | $71.330 million | +19% |
| Gross profit | $51.413 million | $43.392 million | +18% |
| Gross margin | 61% | 61% | Flat |
| Operating income | $16.323 million | $15.864 million | +3% |
| Operating margin | 19% | 22% | Down 3 points |
| Net income | $11.169 million | $9.583 million | +17% |
| Diluted EPS | $2.97 | $2.63 | +13% |
| Adjusted net income | $15.324 million | $12.502 million | +23% |
| Adjusted diluted EPS | $4.08 | $3.43 | +19% |
Revenue growth was led by Biological Indicators, which rose 23% to $33.649 million, and Instruments, which rose 8% to $35.692 million. Continuous Monitoring revenue was essentially flat at $10.792 million, while Cold Chain contributed $4.526 million following the Infitrak acquisition. Biological Indicators and Instruments generated gross margins of 66% and 65%, respectively; Continuous Monitoring declined to 38% from 50%.
Net cash provided by operating activities increased to $16.903 million from $10.816 million. Investing cash outflows were $31.840 million, including $24.111 million for acquisitions and $7.729 million for property, plant, and equipment. Financing cash inflows were $18.620 million, primarily reflecting $25.000 million of debt issuance, partly offset by $6.000 million of debt repayment and $2.303 million of dividends. Cash increased to $5.695 million from $2.034 million, while working capital declined to $13.215 million from $14.965 million.
At March 31, 2016, debt consisted of $27.500 million drawn on the revolving credit line and $17.750 million under the term loan, including $3.000 million classified as current. The credit facility matures June 30, 2020, is secured by company assets, and carries variable interest rates. Mesa was in compliance with its debt covenants at year-end. As of May 31, 2016, outstanding indebtedness was $44.500 million with $22.500 million of unused capacity.
Material Changes Versus the Prior Comparable Period
- Revenue increased 19%, but operating income increased only 3% as general and administrative expense rose 38%, research and development expense rose 21%, and total operating expenses rose 27%.
- General and administrative expense increased by $6.560 million, including higher amortization, personnel and administrative costs, ERP implementation costs, and a $1.709 million litigation settlement expense.
- The Biological Indicators margin improved from 63% to 66%, and the Instruments margin improved from 63% to 65%, primarily from acquisitions, pricing, mix, and volume efficiencies.
- Continuous Monitoring profitability weakened because of product mix and the absence of favorable one-time installation timing in the prior year. Management was implementing a new software and hardware system intended to reduce installation and maintenance costs.
- Goodwill increased to $66.137 million from $44.869 million, and net intangible assets increased to $40.797 million from $33.231 million, largely due to acquisitions.
- Property, plant, and equipment increased to $16.628 million, including $5.970 million spent on a new Bozeman facility expected to cost approximately $14.750 million in total.
- Foreign currency translation produced a $917,000 loss in other comprehensive income, primarily reflecting the stronger U.S. dollar and foreign operations.
Outlook, Commentary, Risks, and Unusual Items
Management stated that Biological Indicators and Cold Chain packaging markets remained strong because of recurring, disposable products and regulatory demand. Management expected Continuous Monitoring revenue to run at approximately $2.5 million to $3.0 million per quarter and expected Cold Chain revenue to grow organically at more than 10% over the next few quarters. Management also expected new products from all divisions during the following year, but provided no consolidated revenue or earnings guidance.
The company completed a cloud-based ERP conversion on October 1, 2015 and expects recurring ERP operating costs of approximately $450,000 annually, excluding additional projects and enhancements.
Key risks include acquisition integration and valuation, substantial goodwill and intangible assets, contingent consideration, variable-rate debt, economic sensitivity of capital equipment purchases, foreign currency exposure, regulatory compliance, product liability, cybersecurity, supply disruptions, competition, tax assessments, litigation, and dependence on distributors. The filing states that there were no legal proceedings pending at the reporting date, but the company settled the Amato litigation for $3.165 million; $1.709 million was recognized as fiscal 2016 expense after insurance and existing accruals.
Infitrak contingent consideration was valued at $9.037 million at March 31, 2016, with potential undiscounted payments ranging from zero to approximately $11.5 million. The liability is payable in two annual installments beginning in the second quarter of fiscal 2017 and may change with actual performance.
Mesa early adopted ASU 2016-09, reducing fiscal 2016 income tax expense by $860,000. Management and the independent auditor concluded that internal control over financial reporting was effective as of March 31, 2016, although the internal controls of Infitrak and North Bay were excluded from management’s assessment because of acquisition timing.
Important Facts for Investors to Verify
- Reconcile the filing period with the requested “2014 Q4” metadata; the filing covers the year ended March 31, 2016.
- Assess whether acquisition-driven revenue growth can continue without further deterioration in operating margins.
- Review Continuous Monitoring’s planned product-system rollout and evidence of margin improvement.
- Evaluate leverage, variable-rate exposure, covenant headroom, and the $22.5 million unused credit capacity reported as of May 31, 2016.
- Monitor Infitrak and PCD earn-out obligations, including potential changes in fair value and cash payments beginning in fiscal 2017.
- Separate GAAP earnings from adjusted net income, which excludes after-tax amortization of acquisition-related intangible assets.
- Review goodwill and intangible-asset balances and future impairment sensitivity following the significant acquisition activity.
- Confirm the financial contribution and integration status of the April 2016 ATS and Pulse acquisitions.
- Consider the impact of the $1.709 million litigation settlement, the $860,000 tax benefit, ERP costs, and foreign-currency losses on recurring earnings.